Biomedcode Hellas SA is a highly innovative Contract Research Organization (CRO) that provides preclinical drug evaluation services to small and large pharmaceutical companies worldwide. Using a unique collection of mouse models that mimic human inflammatory diseases, such as Rheumatoid Arthritis, Intestinal Inflammation, Multiple Sclerosis, Psoriasis, Osteoporosis, Lupus and others, Biomedcode is offering a diverse array of state-of-the-art evaluation platforms ideal for the preclinical testing of therapeutics against human diseases. Biomedcode’s human TNF transgenic models were instrumental in providing in vivo proof of principle on the role of deregulated TNF production underlying the development of chronic polyarthritis and for providing the preclinical rationale for the development of anti-TNF therapies for arthritis. Biomedcode’s services combine scientific consulting and custom-tailored solutions towards optimizing the validation procedure of novel and biosimilar pharmaceuticals, as well as the development of novel therapeutic modalities. Always aiming at high quality services coupled to true customer focus, Biomedcode has built its reputation steadily over the years gaining the trust and respect of its clients, which include worldwide emerging biotech, as well as returning global pharmaceutical companies from Europe, the United States, Asia and Australia, some of them ranked among the top 5 pharmaceutical companies worldwide (0.6 % Greece , 40.1 % rest of Europe , U.S. 37.8 % , 13.1 % Asian , 2.4 % Russia 2.1 % Australia 2.2 % Canada , 1.6 % Israel). In just 7 years since its establishment, Biomedcode has rapidly developed into a highly successful enterprise. Learn more about Biomedcode SA at www.biomedcode.com